[{"id":"0e159834-d55b-493f-b633-ada407fa2107","acronym":"KEYNOTE-603","url":"https://clinicaltrials.gov/study/NCT03313778","created_at":"2021-01-18T16:21:59.009Z","updated_at":"2025-02-25T16:07:00.519Z","phase":"Phase 1","brief_title":"Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors","source_id_and_acronym":"NCT03313778 - KEYNOTE-603","lead_sponsor":"ModernaTX, Inc.","biomarkers":" EGFR • ALK • TMB","pipe":" | ","alterations":" EGFR mutation • ALK positive • ALK translocation • EGFR positive","tags":["EGFR • ALK • TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK positive • ALK translocation • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • MK-3475 SC • intismeran autogene (mRNA-4157)"],"overall_status":"Recruiting","enrollment":" Enrollment 242","initiation":"Initiation: 08/14/2017","start_date":" 08/14/2017","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-01-22"}]